Hadju 1997.

Methods	Design: parallel group randomized trial Duration of study: not reported Duration of follow‐up: 90 days
Participants	Country: Republic of Indonesia Setting: school Number included in study: 507 Age: ≤ 10 years Sex: not reported Inclusion criteria: primary school children attending to grades 1, 2, and 3 Exclusion criteria: children aged > 11 years old or with signs of puberty, with signs of severe protein energy malnutrition, with deformity or congenital abnormality Lost at follow‐up: 177 (34.9%) Number positive for A lumbricoides: 308 Number included in review: 198
Interventions	Treatment strategy: screening and treat all participants Group 1: placebo (n = 69) Group 2: albendazole 400 mg single dose (n = 62) Group 3: albendazole 400 mg twice (n = 67) Group 4: pyrantel pamoate 10 mg/kg single dose (not included in review) Group 5: pyrantel pamoate 10 mg/kg twice (not included in review)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rates, pre‐ and post‐treatment GM epg, ERR Outcomes not included in review: anthropometric measures; efficacy of pyrantel pamoate for A lumbricoides
Notes	Diagnostic technique: modified Kato‐Katz Funding support: Directorate of Higher Education, Government of Indonesia; SmithKline Beecham Ltd. in the UK produced the placebo and albendazole.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "All eligible children were randomized to five treatments groups. Randomization was based on sex and eggs counts of Ascaris."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "The placebo table was similar to the albendazole tablet but pyrantel was different, Children and field workers were not informed of the actual name of both drugs. Each treatment was put in three different boxes label A, B, C. No one except the principal investigator was made aware of the labels." Comment: no details if albendazole twice group received 2 days of placebo.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	177 children lost at follow‐up and not included in analysis.
Selective reporting (reporting bias)	High risk	Adverse events not reported.
Other bias	Low risk	No other obvious source of bias.